Understand the source comparison
FOXO4-DRI vs Other Senolytics: Mechanism and Selectivity
FOXO4-DRI is one of several senolytic compounds under investigation, each targeting different survival pathways in senescent cells. The table below compares FOXO4-DRI to dasatinib+quercetin (D+Q) and fisetin. The two most widely researched alternatives. FOXO4-
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- FOXO4-DRI is one of several senolytic compounds under investigation, each targeting different survival pathways in senescent cells. The table below compares FOXO4-DRI to dasatinib+quercetin (D+Q) and fisetin. The two most widely researched alternatives.
- FOXO4-DRI
- Disrupts p53-FOXO4 interaction, forcing apoptosis in senescent cells
- High. Targets cells with elevated FOXO4 expression
- None published
- Low. Research-grade peptide only
- Most mechanistically specific but least accessible and least studied in humans
- Dasatinib + Quercetin (D+Q)
- Inhibits tyrosine kinases (dasatinib) and BCL-2 family proteins (quercetin)
- Moderate. Broader anti-apoptotic pathway inhibition
- Phase 1–2 trials in idiopathic pulmonary fibrosis, diabetic kidney disease
- Moderate. Dasatinib requires prescription, quercetin is OTC
- Most human data, moderate toxicity profile, accessible through medical channels
- Fisetin
- Inhibits BCL-2, BCL-xL, and other anti-apoptotic proteins
- Moderate to low. Affects multiple cell types
- Phase 2 trial in osteoarthritis, cognitive decline
- High. Available as OTC supplement
- Least specific but most accessible; requires high doses (1000–1500 mg)
- Dasatinib+quercetin has the most robust human evidence. Mayo Clinic trials demonstrated reductions in circulating SASP factors and improvements in physical function in patients with idiopathic pulmonary fibrosis. Fisetin shows promise in preclinical models but requires doses of 20 mg/kg (approximately 1400 mg for a 70 kg adult) to achieve senolytic effects. FOXO4-DRI's specificity is its advantage. It doesn't inhibit pathways in healthy cells. But the lack of human trial data is a significant limitation.